Ipamorelin vs Epithalon
Side-by-Side Comparison
| Attribute | Ipamorelin | Epithalon |
|---|---|---|
| Category | Growth Hormone Secretagogue | Anti-Aging / Telomere |
| Mechanism | Ipamorelin (sequence: Aib-His-D-2Nal-D-Phe-Lys-NH2) selectively binds to the Growth Hormone Secretagogue Receptor (GHS-R1a) on anterior pituitary somatotroph cells, increasing cAMP and activating... | Epithalon (C14H22N4O9, MW ~390 daltons) activates telomerase, particularly the catalytic subunit TERT (telomerase reverse transcriptase), extending telomeres at chromosome ends. |
| Evidence Rating | D — Preclinical | D — Preclinical |
| Clinical Status | Research-only / Not approved for human use | Research-only / No approved human indication in Western countries |
| Safety Profile | Widely regarded as the mildest GHS available; minimal side effects in published animal and human studies; Common: injection site reactions (redness, swelling, bruising) in 15-30% of users, resolving within 24-48 hours | Generally well tolerated; no serious adverse events reported in decades of Russian clinical use; Good safety margin: doses studied range from 0.5 to 5 mg with no dose-limiting toxicity reported |
| Route | Subcutaneous | Subcutaneous |
| Dose Range | 100–300 mcg per injection, 2–3x daily | 5–10 mg/day SC |
| Frequency | 2–3 times daily (typically before meals and before bed) | Once daily |
| Molecular Weight | ~711.9 g/mol | ~390.3 g/mol |
| Half-Life | ~2 hours | Several hours |
Overview
Ipamorelin and Epithalon are both research peptides studied across multiple applications. This comparison examines their mechanisms, evidence base, dosing protocols, and safety profiles to help researchers understand the key differences and overlaps.
Ipamorelin — Mechanism & Evidence
Ipamorelin is the most selective growth hormone secretagogue (GHS) available, a synthetic pentapeptide (MW ~711.86 g/mol, formula C38H49N9O5) that stimulates pulsatile GH release from the pituitary gland without significantly affecting cortisol, prolactin, or appetite. It is widely regarded as the mildest GHS, making it popular in anti-aging, body composition, and recovery contexts. However, research on ipamorelin is limited, and it is not FDA-approved for any indication.
Key claims: Increases growth hormone levels; Improves body composition; Improves sleep quality.
Epithalon — Mechanism & Evidence
Epithalon is a synthetic tetrapeptide (Ala-Glu-Asp-Gly, MW ~390 g/mol) developed by Russian gerontologist Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology. Its primary mechanism involves telomerase activation to maintain telomere length. Secondary mechanisms include melatonin enhancement via pineal gland restoration, hormonal balance improvement, and antioxidant defense. Extensive Russian research spanning 20+ years of clinical use reports safety and efficacy, but Western clinical trials remain minimal. Animal studies show lifespan extension of up to 13.3% in the last 10% of survivors (p<0.05).
Key claims: Activates telomerase and extends telomeres; Extends lifespan in animal models; Restores melatonin production and sleep quality.
Shared Research Applications
Both peptides are studied for: Anti-Aging.
Ipamorelin is also researched for: Body Composition, Sleep.
Epithalon is also researched for: no additional unique applications.
Safety Considerations
Ipamorelin: Widely regarded as the mildest GHS available; minimal side effects in published animal and human studies Common: injection site reactions (redness, swelling, bruising) in 15-30% of users, resolving within 24-48 hours Common: mild temporary "head rush" or flushing immediately after injection due to sudden vasodilation
Epithalon: Generally well tolerated; no serious adverse events reported in decades of Russian clinical use Good safety margin: doses studied range from 0.5 to 5 mg with no dose-limiting toxicity reported Mild headaches, dizziness, and GI discomfort possible
Related Products
Related Research News
Epithalon Research: Telomerase Activation and Longevity Effects
Epithalon, a synthetic tetrapeptide (Ala-Glu-Asp-Gly, AEDG), activates telomerase in human cells, leading to telomere elongation according to studies by Vladimir Khavinson's group. Research also shows lifespan extensions of 6% to 25% in rodents, reduced tumor incidence, and restored melatonin rhythms in aging models. These findings link the peptide to pineal gland function and oxidative stress reduction, though independent replication remains limited.
CJC-1295 with DAC and Ipamorelin: Growth Hormone Research Guide
CJC-1295 with DAC and Ipamorelin represent key compounds in growth hormone research, targeting distinct pathways for GH and IGF-1 signaling. CJC-1295 with DAC acts as a long-acting GHRH analogue with a half-life of 5.8 to 8.1 days, while Ipamorelin functions as a selective growth hormone secretagogue via the ghrelin receptor. Together, they support studies on metabolism, recovery, and body composition.
Ipamorelin vs GHRP-2: Which Offers More Targeted GH Release?
Ipamorelin and GHRP-2 both stimulate growth hormone release via the ghrelin receptor, but Ipamorelin provides more selective action with minimal impact on other hormones like ACTH and cortisol. GHRP-2 delivers stronger GH pulses alongside broader endocrine effects. Combining them can enhance overall GH output through additive receptor stimulation.